The increased recruitment of TILs and their intratumoral expansion, with the combination of IL-2 variant targeting fibroblast activation protein-alpha with anti-HER2 drugs, may help to better position immunotherapy in HER2+ BC in the future. Here, ERBB2 is linked to breast cancer.